Ranbaxy Laboratories Ltd, India's top drugmaker by sales, said it expected to get US approvals for a paediatric dosage of its generic version of Augmentin, GlaxoSmithKline's blockbuster antibiotic, within a month.\n\n\n\n
Data late on Wednesday showed consumer price inflation eased more than-expected to a 25-month low of 8.10 per cent in February, while industrial output unexpectedly expanded, albeit only by 0.1 per cent.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
A US district court has dismissed a petition by Israel's Taro Pharmaceutical Industries to block leading Indian drug maker Sun Pharma from launching an open offer to acquire majority stake in the former.
The FDA has stepped up its efforts to ensure drug safety in recent months.
Three different invitations were sent out for the wedding and the receptions with top-run guests being sent a large red box that contained an intricate chest incorporating a mini silver temple featuring gold idols of various Hindu deities, including Lord Ganesh, Radha-Krishna, and Goddess Durga.
With an expected earnings growth of 15 per cent, benchmark index Nifty 50 may hit 24,500 level by December 2024 and move further to surpass the level of 26,500 by December 2025, Emkay Investment Managers said on Tuesday. The 50-share Nifty settled at 22,888.15 on Tuesday. In the previous day, it hit a new lifetime peak of 23,110.80.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
RIL is grappling with other priorities -- sliding oil prices, shrinking refining margins and a battle with the Anil Ambani group over the supply of gas. The plan was to build an integrated pharma company in two to three years, on the lines of large domestic majors such as Ranbaxy's or Dr Reddy's Laboratories. Instead, the plan has been modified to being a start-up bulk drug manufacturing company that will launch six bulk drugs or active pharmaceutical ingredients by 2010.
'The deaths of the children in the Gambia would batter India's reputation as the developing world's pharmacy.'
Sun Pharmaceutical Industries and Lupin Ltd will soon add another generic drug each to their US product basket. The companies received approvals from the US drug regulator to market generic equivalent of Pfizer's Dilantin Kapseals and Abbot's Mavik r
The stocks are largely from sectors such as chemicals, finance and cement, which struggled earlier but the worse seems to be behind them.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
Equity benchmark indices Sensex and Nifty settled higher on Thursday, powered by a rally in banking and power stocks amid a largely firm trend in global markets. The stock markets mostly traded range-bound in the absence of any major trigger and persistent foreign capital outflows, traders said. The 30-share BSE Sensex rose 144.31 points, or 0.18 per cent, to settle at 81,611.41.
Ranbaxy Laboratories Ltd on Friday raised its equity stake to 50 per cent in Nihon Pharmaceutical Industry.
There are just 1,500 drug inspectors responsible for more than 10,000 factories in India
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday.
Plans to set up an integrated pharma firm in a phased manner.
Dhirubhai Ambani lived in a one-room chawl in Mumbai with his wife and children and went on to establish the Reliance Group.
In many cases, of course, financial institutions like Life Insurance Corporation or government-controlled banks have come to the rescue of Indian companies facing takeover threats.
Biocon Ltd on Tuesday said it has earned the distinction of being the only Asian biopharma company to feature among the top biotechnology employers in the world as ranked by Science magazine.
As part of the charm offensive, New Delhi has invited global regulators -- including the FDA -- to visit Indian production units to get first-hand evidence of measures taken to ensure the quality of locally manufactured generics.
Stock markets are expected to remain under pressure this week due to the overhang of US presidential polls and uncertainty over global growth due to resurging cases of coronavirus, according to analysts.
The deal would involve Pfizer paying with 11.3 of its shares for each Allergan share.
The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India.
A critical drug developed on a DRDO technology for radiological and nuclear emergencies has received approval from the Drugs Controller General of India (DCGI), the defence ministry said on Tuesday.
The fire broke out after a blast at United Phosphorus Ltd's plant in Jhagadia GIDC industrial area, said inspector P H Vasava of the local police station.
Companies are drawn to the parks by the infrastructure and ready-to-occupy land.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.
Generic drugmakers cannot be sued under state law for adverse reactions to their products.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
This acquisition marks Lupin's foray into the Japanese branded market in-line with aspirations to build business globally.
The claims were made after the Income Tax department had on July 6 raided 36 premises of the Bengaluru-based Micro Labs Ltd. across nine states.
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
